NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
22 hedge funds and large institutions have $340K invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Holders
22
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$48.6K | |
| 2 | +$42K | |
| 3 | +$15.6K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$10 |
Top Sellers
| 1 | -$10.7K | |
| 2 | -$1.11K | |
| 3 | -$263 | |
| 4 |
First Manhattan
New York
|
-$261 |